Genesis Framework Word Press Theme Review Is It Good
http://tinyurl.com/8kodpon Genesis or Thesis plus Themedy "Themedy" like remedy (for what ails ya). We create designs for Thesis from DIY Themes Genesis by...
By: JeniferGFinch
Here is the original post:
Genesis Framework Word Press Theme Review Is It Good - Video
PRESS RELEASE: Balda reports positive financial performance and announces a further special dividend
DGAP-News: Balda AG / Key word(s): Final Results Balda reports positive financial performance and announces a further special dividend
12.12.2013 / 07:56
=--------------------------------------------------------------------
- Substantial increase in sales to just under EUR 60 million
- Comprehensive income of EUR 13.5 million
- Proposal to pay a further special dividend of EUR 1.50 per share
- COO Oliver Oechsle: Our mission is to enable growth for the Balda Group
- CFO Dieter Brenken: Balda has a solid financial foundation
Bad Oeynhausen, 12 December 2013 - The Balda Group showed strong financial performance in the 2012/2013 financial year. Consolidated sales from continuing operations amounted to EUR 59.9 million. Adjusted for extraordinary items, earnings before interest, taxes, depreciation and amortization (EBITDA) improved by EUR 6.7 million over the 2012 short financial year to EUR 4.1 million; consolidated EBITDA including extraordinary items totaled EUR 4.9 million. The Group's comprehensive income was EUR 13.5 million.
Read more from the original source:
PRESS RELEASE: Balda reports positive financial performance and announces a further special dividend
PRESS RELEASE: Epigenomics AG: Epigenomics AG Welcomes Reimbursement for Septin9 Testing by French Insurance Provider
DGAP-News: Epigenomics AG / Key word(s): Miscellaneous Epigenomics AG: Epigenomics AG Welcomes Reimbursement for Septin9 Testing by French Insurance Provider
12.12.2013 / 08:45
=--------------------------------------------------------------------
Berlin, Germany, and U.S.A., December 12, 2013 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that MACSF (Mutuelle d'Assurance du Corps de Sante Franais), the leading French supplementary insurance provider for the medical community, will provide the blood-based Septin9 test for the early detection of colorectal cancer (CRC) as part of their additional health insurance program. MACSF will reimburse EUR 50 on what its policy holders pay for undergoing Septin9 testing.
MACSF offers about 800.000 policy holders from the medical community and their families, such as doctors from the private and public sector, other medical or paramedical workers including medical students an additional health insurance, called 'Mutuelle'. After Swiss Life announced to provide Septin9 as part of its preventive health program in July 2012, MACSF is the second healthcare provider in France and the first 'Mutuelle' to reimburse blood-based colorectal cancer screening.
Dr. Thomas Taapken, CEO/CFO of Epigenomics, commented: 'We are extremely pleased to experience this growing support by French insurance providers. The fact that also MACSF now offers blood-based Septin9 tests to its customers shows the importance of an alternative convenient and non-invasive screening method. And, as their policy holders originate primarily from the medical community, we also hope to raise awareness and convince doctors of our Septin9-based test Epi proColon(R), so that they increasingly recommend it to their patients'.
- Ends -
About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company's products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics' lead product, Epi proColon(R), is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A and China. The Company's technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.
Read the original:
PRESS RELEASE: Epigenomics AG: Epigenomics AG Welcomes Reimbursement for Septin9 Testing by French Insurance Provider
PRESS RELEASE: Formycon AG signs first biosimilar licensing agreement with Santo Holding GmbH
DGAP-News: Formycon AG / Key word(s): Incoming Orders Formycon AG signs first biosimilar licensing agreement with Santo Holding GmbH
12.12.2013 / 07:25
=--------------------------------------------------------------------
- Out-licensing of first biosimilar from Formycon's product development pipeline
- Successful long-term positioning as a global biosimilars development company
- Formycon to receive success-based payments in the three-digit million euro range
Munich - Formycon AG today announced the signing of an exclusive, worldwide licensing agreement with Santo Holding GmbH, owned by the well noted German pharmaceutical investors Andreas and Thomas Strngmann, granting rights to the first biosimilar drug of Formycon's development pipeline. Under the terms of the agreement, Santo Holding will assume responsibility and bear the costs for the development and commercialization of the Formycon biosimilar drug. Formycon will perform the entire further development of the product for Santo Holding.
Formycon will receive an immediate, single-digit million euro up-front payment and will be entitled to additional payments in the three-digit million euro range based upon the attainment of specific regulatory and sales results.
'I am delighted that we have been able to gain Santo Holding for this cooperation arrangement with Formycon. This attests to the strength of Formycon's long-term strategic orientation as a global biosimilars development company. I would also like to take this opportunity to thank the entire team at Formycon, which has worked so hard to bring about this successful outcome,' declared Dr. Carsten Brockmeyer, CEO of Formycon AG.
More:
PRESS RELEASE: Formycon AG signs first biosimilar licensing agreement with Santo Holding GmbH
LANSING The word "selfie" is spoken even at the Michigan Supreme Court.
Selfie refers to someone who takes their own picture, usually with a smartphone. Chief Justice Robert Young Jr. used the word Wednesday when talking about a Detroit-area judge who took a picture of his fit, shirtless frame and sent it to a female sheriff's deputy.
Justice Bridget McCormack jumped in and said, "I want the record to reflect that the chief justice just used the word 'selfie.'"
Young, a conservative, bow-tied justice, says it shows that he's in tune with today's culture.
Britain's Oxford University Press recently declared "selfie" the word of the year. It publishes Oxford dictionaries.
If you enjoy the content on the Crain's Detroit Business Web site and want to see more, try 8 issues of our print edition risk-free. If you wish to continue, you will receive 44 more issues (for a total of 52 in all), including the annual Book of Lists for just $59. That's over 55% off the cover price. If you decide Crain's is not for you, just write "Cancel" on the invoice, return it and owe nothing. The 8 issues are yours to keep with no further obligation to us. Sign up below.
Offer valid for new MI subscribers only. Non-MI subscribers - $79. All other Foreign - $127.
If you enjoy the content on the Crain's Detroit Business Web site and want to see more, try 8 issues of our print edition risk-free. If you wish to continue, you will receive 44 more issues (for a total of 52 in all), including the annual Book of Lists for just $59. That's over 55% off the cover price. If you decide Crain's is not for you, just write "Cancel" on the invoice, return it and owe nothing. The 8 issues are yours to keep with no further obligation to us. Sign up below.
More here:
'Selfie' is on the record at Michigan Supreme Court